Why RDNT Stock slipped -0.53% Today — RQD Quant Desk Flash

RadNet Inc. Scores 57 out of 100, grade D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

• Fundamental Cash Engine: 12 / 20. this pillar reflects ROIC of 3.5% and an FCF yield of 5.16%. For an investor, the return on invested capital is modest, while free cash flow generation provides some support relative to the share price.
• Whale 13F Flow: 11 / 20. this pillar measures institutional accumulation and options positioning. The score is below midpoint, indicating limited evidence of strong institutional conviction in the source data.
• Insider Conviction: 10 / 20. this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score is weak, suggesting insider and congressional activity does not provide a strong confirming signal.
• Macro Regime Fit: 14 / 20. beta is 1.0 with sector sensitivity considered. This is the strongest pillar, meaning the stock's market sensitivity is roughly in line with the broad market rather than amplifying it.
• Forensic Balance Sheet: 10 / 20. this pillar reflects Altman Z of 2.15, Piotroski F of 6/9, and Debt/Equity of 0.98. The Piotroski reading is a relative positive, while the leverage ratio and Z-score weigh on the score.

Taken together, the rating points to a stock whose upside depends on improving operating returns and cash conversion, with limited near-term confirmation from institutional or insider behavior. Per the market data, the stock trades at an EV/EBITDA of 98.3, a valuation level that leaves limited room for error if earnings growth does not follow. Supporting facts are a 5.16% FCF yield and a balance sheet that is not in distress by the Altman measure, while the key drags are thin ROIC, a negative net margin, and elevated leverage.

RadNet Inc. Is a NASDAQ-listed issuer classified in the Health Care sector and the Medical Specialities industry,..8B.

Revenue rose from $1.62B in FY 2023 to $2.04B in FY 2025, while operating income declined from $104.6M in FY 2024 to $62.0M in FY 2025 and net income swung to -$18.6M in FY 2025. Per the market data, operating margin is 3%, net margin is -0.9%, and gross margin is 0%, with ROIC at 3.5%. The Altman Z-Score is 2.15 and the Piotroski F-Score is 6/9. Debt exceeded cash in FY 2025 ($1.06B versus $767.2M), consistent with the Debt/Equity of 0.98 cited in the rating.

• 🐂 Primary Bull Case: Macro Regime Fit (14/20) is the strongest pillar, with beta of 1.0 and a 5.16% FCF yield providing cash-based support against the stock's price. With Fundamental Cash Engine at 12/20 (ROIC 3.5%, FCF yield 5.16%) and Institutional Whale Flow at 14/20, sustained execution supports upside toward the top of the $50.82 – $85.84 52-week range.
• 🐻 Primary Bear Case: An EV/EBITDA of 98.3 combined with a net margin of -0.9% and debt of $1.06B exceeding cash of $767.2M leaves little valuation cushion. Investors must weigh current valuation and 98.3x EV/EBITDA against 3.0% operating margins and a 1.00 macro beta if sector demand softens.

The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations beyond the Health Care / Medical Specialities classification. An investor should note that second-order ripple effects cannot be mapped from the provided sources. The one cross-check the data permits is the M&A reference in the Seeking Alpha headline, which points to a possible corporate-action catalyst, but the source does not detail its counterparty or implications.

• Key Question #1: What drove the swing from positive net income in FY 2023 and FY 2024 to a net loss of -$18.6M in FY 2025, and how much of the operating income decline is attributable to specific segments?
• Key Question #2: What is the composition of the $1.06B debt, including maturity profile and interest burden, and how does it relate to the Debt/Equity of 0.98?
• Key Question #3: What is the substance of the M&A call referenced in the Seeking Alpha item, and what is the expected impact on the balance sheet and revenue base?